BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181115
DTEND;VALUE=DATE:20181218
DTSTAMP:20260730T114703
CREATED:20181115T151549Z
LAST-MODIFIED:20181115T151549Z
UID:20850-1542240000-1545091199@ces.b2sg.org
SUMMARY:Clinical Development Scientist - Oncology
DESCRIPTION:Your Responsibilities: \nReporting to the Medical Director\, Therapeutic Area\, the Clinical Development Scientist\, aligned by asset\, will work closely with the MDL/PPL/PT in the development and global execution of the clinical development plan including regulatory submissions and life-cycle plans. In addition\, you would work closely with the other global team functional leads and Regional Heads to provide “enterprise thinking” in the development of the overall Oncology portfolio. \nYou will be expected to have a strong scientific and clinical research background and be able to take a lead role in the clinical and scientific responsibilities of oncology clinical trials. \nKey Responsibilities: \n\nProvide strategic leadership for the development of an asset or portfolio of assets.\nExecute the broad strategy and vision of the organization through the leadership of a multi-disciplinary matrix team within the R&D organization.\nHelp to define and mitigate key development risks of a compound.\nWork closely with functional lines to evaluate and identify key clinical and pre-clinical data required for decisions around medicine development.\nFacilitator of decision-making both within the project team and with external stake-holders.\nAccountable for quality\, timely\, and on-budget delivery of the asset clinical development plan and studies\nDirect study responsibility\, if required\nCollaboration with the MDL & PPL(s) to plan and implement strategy to address asset program requirements in alignment with Oncology R&D goals\nExcellence in the clinical research staffs contribution to successful regulatory approvals\, reimbursable medicines\, and lifecycle management\nIdentification and sharing of best practices with oversight for the implementation of these best practices into business processes\nClose collaboration with other matrixed functions for in-stream\, end-to-end process flow\, document preparation\, data review and submissions.\nCreation and fostering of strong strategic partnerships with key internal stakeholders and strategic external partners\n\n\nLI-GSK\n\n\n\nWhy You? \n• Bachelors Degree \n\nMinimum of 10 years of relevant clinical drug development experience\nDemonstrated ability to lead in a heavily matrixed environment\nAbility to influence staff and stakeholders to adapt to positive change\n\n\n\nPreferred qualifications: \n• Master’s degree or beyond \n\nComprehensive knowledge of asset and asset strategy highly recommended
URL:https://ces.b2sg.org/event/gsk-15nov18/
LOCATION:gsk\, 1250 S Collegeville Rd\, Collegeville\, PA\, 19426\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/10/GSK-1-e1507913461300.jpg
END:VEVENT
END:VCALENDAR